Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Human Pheromone Sciences, ACI, Inc. and Marilyn Miglin Announce the Introduction of Their Initial Fragrance on Home Shopping Network
Published: October 29, 2009
SAN JOSE, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Human Pheromone Sciences, Inc. (OTC Bulletin Board: EROX) ("HPS" or "the Company"), ACI, Inc. and Marilyn Miglin LLC announced the initial product generated by their collaborative efforts to create a fragrance collection, Marilyn Miglin's Sixth Sense, will be introduced on Home Shopping Network (HSN)., commencing Sunday, November 1, 2009.
The parties were introduced through New York City based BIG (Brand Intelligence Group, Inc.) who handles the branding and licensing of several fashion, beauty and lifestyle brands. "We are delighted to join together two innovative and dynamic companies to collaborate on a new venture," said Deborah Moses, co--founder of BIG. "Marilyn Miglin is synonymous with fragrance and understanding the tastes of today's consumer. So it was only natural for her to look toward technology to enhance her 30(th) fragrance introduction into the market place with Marilyn Miglin's Sixth Sense."
This is a groundbreaking new essence, an intriguing marriage of sensuality and empowerment that delivers a new sensory experience. The wearer is more confident and radiant with her presence heightened to all of those around her.
The fragrance is a unique addition to Marilyn Miglin's highly successful portfolio of fragrances with a sensory-dynamic quality that enhances allurement and self-assurance offering a truly new experience in fragrance. "It's a flawless collaboration of Marilyn, her perfumers and the HPS chemists to create a mysterious, ultra feminine and elegant scent," said Joanne Benjamin, President of ACI, a vendor to HSN for over 20 years. "Marilyn Miglin's Sixth Sense will provide a warm, long lasting, sensual background that awakens the provocateur in the wearer."
Human Pheromone Sciences, Inc. is a technology-based company, whose products include prestige and mass-priced fragrances, toiletries and environmental products. The Company has Licensing and Distribution Agreements with Johnson & Johnson, Inc., Schwarkopf and Henkel, Dial Corporation and an exclusive agreement with Pheromone International Co., Ltd. in Taiwan. These products contain mood-enhancing compounds, whose efficacy has been validated at leading universities around the world, and whose use is covered under United States and foreign patents. The Company is also involved in research and product development efforts on new compounds that have been previously identified as stimulating the emotional centers of the human brain and have worldwide patents pending on another compound originally found in Coral Reefs. Further information is available online at www.erox.com.
The statements in this news release may contain forward-looking statements that involve risks and uncertainties that could cause results to differ from predicted results. Further information on factors that could affect the Company's results is detailed in the Company's annual report to shareholders on Form 10-K for the year ended December 31, 2008, and Form 10-Q for the quarter and six months ended June 30, 2009, as filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements.
SOURCE Human Pheromone Sciences, Inc.
More Press Releases
Human Pheromone Sciences Announces Third Quarter Results
November 13, 2009 - PR Newswire
RELATED ADSwhat are related ads?
PDUFA action date 2/11/2010
8/25/2009
Labopharm's response for novel trazodone formulation accepted by FDA as complete - Designated as Class 2 resubmission
- New PDUFA action date assigned -
LAVAL, QC, Aug. 25 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced the U.S. Food and Drug Administration (FDA) has accepted Labopharm's response regarding its novel formulation of the antidepressant trazodone as complete and designated it as a Class 2 resubmission. The FDA has assigned Labopharm a new Prescription Drug User Fee Act (PDUFA) action date of February 11, 2010.
Labopharm received a complete response letter from the FDA on July 17, 2009 indicating the Company's new drug application (NDA) for its novel trazodone formulation could not be approved in its present form due to deficiencies following the FDA's inspection of the manufacturing facility of the active pharmaceutical ingredient (API) supplier, Angelini. The letter did not raise any efficacy or safety issues. Angelini submitted an action plan addressing the deficiencies to the FDA on July 24, 2009.
Labopharm continues to prepare for the commercialization of its novel antidepressant and, pending FDA approval, intends to launch in the U.S. shortly thereafter.
About Labopharm Inc.
Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is now available in 17 countries around the world, including the U.S., Canada, major European markets and Australia. The Company's second product, a novel formulation of trazodone for the treatment of major depressive disorder, is under regulatory review in the U.S. by the FDA. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit www.labopharm.com.
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the uncertainties related to the regulatory process in various countries for the approval of the Company's products and the successful commercialization of the products throughout the world if they are approved. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.
SOURCE Labopharm Inc.
At Labopharm: Mark D'Souza, Senior Vice-President and Chief Financial Officer, Tel: (450) 686-0207; At The Equicom Group: Jason Hogan, Media and Investor Relations, Tel: (416) 815-0700, jhogan@equicomgroup.com; French: Joe Racanelli, Tel: (514) 844-7997, jracanelli@equicomgroup.com
Here are some biotech co. You will have to do some DD. on the FDA thing.
http://www.financialchat.com/blogs/biotech-cash-worksheet
When you find the item each co is working on,go to this site with the drug.
WWW.CLINICALTRIALS.GOV
Yes and YES.
??Got TNFerade? Jailhouse injected me with some and now i think 1% like captain. ARGG!!!!!!!!!
Did Bubba administer that injection??
you have to like the potential for GNVC.
http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/Overview/ucm119477.htm
Check out youtube invive colloidal silver video
http://www.invive.com/
GNVC
COLUMBUS DAY CONTEST
ALY
colloidal silver
also
www.stockseasonality.com
What a bargain! I bought a 1 year subscription for the small price of $179.95 and the first trade paid for the subscription plus my cell phone for a two year contract; which enables me to trade on the go. Stockseasonality is now in the process of changing my ZIP CODE and this should take place some time in 2010.
WU and the info you learn from stockseasonality will make you a better trader
Apollo Gold Second Quarter 2009 Gold Production from Its Black Fox Mine
Press Release
Source: Apollo Gold Corporation
On Tuesday July 28, 2009, 9:00 am EDT
Buzz up! 0
Print
Companies: Apollo Gold Corp.
DENVER--(BUSINESS WIRE)--Apollo Gold Corporation (“Apollo” or “we”) (TSX: APG - News) (NYSE Amex: AGT) is pleased to update the market on the second quarter 2009 gold production and progress at its Black Fox mine located near Timmins, Ontario.
Related Quotes
Symbol Price Change
AGT 0.47 +0.02
On June 2, 2009, we announced that our Black Fox project had poured its first gold bars during the last week of May and was in commercial production. We are pleased to report that during the two months of May and June 2009 the Black Fox mill processed 78,000 tonnes of ore at an average grade of 5.1 grams of gold per tonne ore to produce 11,860 ounces of gold (recovery approximately 92.5%). The average mill throughput rate was therefore approximately 1,280 tonnes per day.
R. David Russell, President and CEO of Apollo, stated: “On June 2, 2009, we announced that our near-term objectives at Black Fox were (i) to operate the mill at a steady rate of 1,500 tonnes of ore per day for June 2009, (ii) to commission the new crushing circuit in early July 2009 and (iii) to increase throughput to our target of 1,800 tonnes per day by late September 2009. Due to a few minor mechanical challenges, we were unable to achieve the steady state throughput at the mill of 1,500 tonnes per day during the first half of June, but we were able to achieve it throughout the second half of June 2009. I am also pleased to announce that we did commission the new crushing circuit during the first week of July, on schedule, and that, for the first 26 days of July 2009 the mill throughput has averaged 1,800 tonnes per day.”
Apollo Gold Corporation
Apollo is a gold mining and exploration company which operates the Black Fox mine in Ontario, Canada, and the Huizopa project, an early stage exploration project in the Sierra Madres in Chihuahua, Mexico. Apollo also owns the Montana Tunnels mine, which is a 50% joint venture with Elkhorn Tunnels, LLC, in Montana, which was placed on care and maintenance on April 30, 2009.
FORWARD-LOOKING STATEMENTS
This press release includes “Forward-Looking Statements” within the meaning of section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements can be identified by the use of words such as “may,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “schedules,” “targets,” “predicts,” “intends,” “continue,” or the negative of such terms, or other comparable terminology. All statements regarding future throughput rates at the Black Fox mill are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from these forward-looking statements include: additional operational, geotechnical, processing problems at the Black Fox mine and mill, unexpected changes in business and economic conditions, political or economic instability, significant decreases in gold prices, difficulties or delays in permitting at Black Fox, changes in interest and currency rates, local and community impacts and issues, labor accidents, environmental risks and other factors disclosed under the heading “Risk Factors” in Apollo’s most recent annual report on Form 10-K filed with the United States Securities and Exchange Commission and elsewhere in Apollo’s documents filed from time to time with the Toronto Stock Exchange, The NYSE Amex exchange, The United States Securities and Exchange Commission and other regulatory authorities. All forward-looking statements included in this press release are based on information available to Apollo on the date hereof. Apollo assumes no obligation to update any forward-looking statements.
Contact:
Apollo Gold Corporation
Marlene Matsuoka, 720-886-9656 Ext. 217
Investor Relations
Toll Free: 1-877-465-3484
ir@apollogold.com
VICL
Vical Announces News Release and Conference Call/Webcast Schedule to Present TransVax(tm) CMV Vaccine Phase 2 Interim Efficacy Results
Press Release
Source: Vical Incorporated
On Tuesday July 7, 2009, 6:30 am EDT
Buzz up! 0
Print
Companies: Vical inc.
SAN DIEGO, July 7, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL - News) today announced that the company will report tomorrow the interim efficacy results from the company's Phase 2 trial evaluating the potential for its TransVax(tm) therapeutic DNA vaccine to prevent cytomegalovirus (CMV) reactivation and disease in immunosuppressed stem cell transplant recipients. CMV and organ transplant expert Mark D. Pescovitz, M.D., Professor of Surgery and Microbiology & Immunology, and Vice Chair of Research in Surgery at the Indiana University School of Medicine, is scheduled to join Vical management on the call.
Related Quotes
Symbol Price Change
VICL 2.67 +0.18
The company will release summary results before the opening of trading on Wednesday, July 8, and conduct an audio-only conference call and audio/slide webcast at 11 a.m. Eastern Time on Wednesday, July 8, to discuss additional details of the results with invited analysts and institutional investors. The call is open on a listen-only basis to any interested parties. The webcast audio and slides also will be available live and archived through the Events page of the company's website at www.vical.com.
To listen to the conference call, dial (877) 857-6177, or (719) 325-4838 for international participants. A replay of the call will be available for 48 hours beginning about two hours after the call. To listen to the replay, dial (888) 203-1112, or (719) 457-0820 for international participants, and enter conference identification number 4682239. For further information, contact Vical's Investor Relations department by phone at (858) 646-1127 or by e-mail at info@vical.com.
About Vical
Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at www.vical.com.
The Vical Incorporated logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=5768
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the company's focus, collaborative partners, product candidates, and developmental status. Risks and uncertainties include whether Vical or others will continue development of TransVax(tm) or any other product candidates; whether TransVax(tm) or any other product candidates will be shown to be safe and effective; the timing, nature and cost of clinical trials; whether Vical or its collaborative partners will seek or gain approval to market TransVax(tm) or any other product candidates; the dependence of the company on its collaborative partners; and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.
Contact:
Vical Announces News Release and Conference Call/Webcast Schedule to Present TransVax(tm) CMV Vaccine Phase 2 Interim Efficacy Results
Press Release
Source: Vical Incorporated
On Tuesday July 7, 2009, 6:30 am EDT
Buzz up! 0
Print
Companies: Vical inc.
SAN DIEGO, July 7, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL - News) today announced that the company will report tomorrow the interim efficacy results from the company's Phase 2 trial evaluating the potential for its TransVax(tm) therapeutic DNA vaccine to prevent cytomegalovirus (CMV) reactivation and disease in immunosuppressed stem cell transplant recipients. CMV and organ transplant expert Mark D. Pescovitz, M.D., Professor of Surgery and Microbiology & Immunology, and Vice Chair of Research in Surgery at the Indiana University School of Medicine, is scheduled to join Vical management on the call.
Related Quotes
Symbol Price Change
VICL 2.67 +0.18
The company will release summary results before the opening of trading on Wednesday, July 8, and conduct an audio-only conference call and audio/slide webcast at 11 a.m. Eastern Time on Wednesday, July 8, to discuss additional details of the results with invited analysts and institutional investors. The call is open on a listen-only basis to any interested parties. The webcast audio and slides also will be available live and archived through the Events page of the company's website at www.vical.com.
To listen to the conference call, dial (877) 857-6177, or (719) 325-4838 for international participants. A replay of the call will be available for 48 hours beginning about two hours after the call. To listen to the replay, dial (888) 203-1112, or (719) 457-0820 for international participants, and enter conference identification number 4682239. For further information, contact Vical's Investor Relations department by phone at (858) 646-1127 or by e-mail at info@vical.com.
About Vical
Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at www.vical.com.
The Vical Incorporated logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=5768
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the company's focus, collaborative partners, product candidates, and developmental status. Risks and uncertainties include whether Vical or others will continue development of TransVax(tm) or any other product candidates; whether TransVax(tm) or any other product candidates will be shown to be safe and effective; the timing, nature and cost of clinical trials; whether Vical or its collaborative partners will seek or gain approval to market TransVax(tm) or any other product candidates; the dependence of the company on its collaborative partners; and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.
Contact:
Serrapeptase info at http://www.serrapeptase.info/
toddao,have you used serrapeptase? I did some DD on it and sounds like the ticket.
Serrapeptase
The natural Chelation-Anti-Inflammatory Serrapeptase has had wide clinical use - spanning over twenty-five years throughout Europe and Asia - as a viable alternative to salicylates, ibuprofen and the more potent NSAIDs. Unlike these drugs, Serrapeptase is a naturally occurring, physiological agent with no inhibitory effects on prostaglandins and is devoid of gastrointestinal side effects.
Serrapeptase is a proteolytic enzyme isolated from the micro-organism Serratia E15. This enzyme is naturally processed commercially today through fermentation and was discovered in the silkworm intestine. This immunologically active enzyme is completely bound to the alpha 2 macroglobulin in biological fluids. Histological studies reveal powerful anti-inflammatory effects of this naturally occurring enzyme.
Serrapeptase digests non-living tissue, blood clots, cysts, and arterial plaque and inflammation in all forms. The late German physician, Dr. Hans Nieper, used Serrapeptase to treat arterial blockage in his coronary patients. Serrapeptase protects against stroke and is reportedly more effective and quicker than EDTA Chelation treatments in removing arterial plaque. He also reports that Serrapeptase dissolves blood clots and causes varicose veins to shrink or diminish. Dr. Nieper told of a woman scheduled for hand amputation and a man scheduled for bypass surgery who both recovered quickly without surgery after treatment with Serrapeptase.
"Party Bash 4th of July Contest Pick"
RAE
CYCC
Press Release Source: Cyclacel Pharmaceuticals, Inc.
Sapacitabine Has Anti-Cancer Activity in Combination With Targeted Agents and Other Nucleoside Analogs
Preclinical Data Reported At European Hematology Association Congress
On Monday June 8, 2009, 10:19 am EDT
Buzz up! Print
Related: Cyclacel Pharmaceuticals, Inc.
BERKELEY HEIGHTS, N.J., June 8, 2009 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC - News; Nasdaq:CYCCP - News) announced that Cyclacel scientists reported preclinical data supporting potential combinations of sapacitabine, a novel nucleoside analog, with novel targeted agents and other nucleoside analogs for the treatment of cancer. The combinations exploit sapacitabine's unique mechanism of action and were shown to be effective in models of leukemia and solid tumors. The data were presented at a poster presentation on Saturday, June 6 at the 14th Congress of the European Hematology Association (EHA) in Berlin, Germany.
Related Quotes
Symbol Price Change
CYCC 1.09 +0.18
"We are encouraged by the wide spectrum of anti-cancer agents that result in synergy when combined with sapacitabine. The EHA data extend previously reported data and support clinical evaluation of sapacitabine given with various anti-cancer agents as combination treatment for leukemia and other cancers," said Spiro Rombotis, President and CEO. "A week ago at the ASCO conference we reported interim Phase 2 data that pave the way for a pivotal trial of sapacitabine as a single agent in elderly patients with leukemia. We look forward to developing the broad therapeutic potential of sapacitabine to benefit patients in need of new treatment options."
The results, arising from a combination screen of over 30 compounds from several chemical families, showed robust synergy when sapacitabine was combined with inhibitors of cell cycle checkpoints, cell survival, and DNA repair, including targeted inhibitors of ATM, BCL2, CHK1, DNA-PK and PARP.
In addition, increased apoptosis or cancer cell death was observed when sapacitabine was administered in combination with other nucleoside analogs which inhibit ribonucleotide reductase, such as clofarabine and gemcitabine.
The findings extend previously reported data supporting the combination of sapacitabine with demethylating agents or HDAC inhibitors.
Specific targeted molecules presented in the abstract, inducing synergy when given in combination with sapacitabine, included: ABT-888 (PARP inhibitor), ABT-737 (BCL-2 inhibitor), KU55933 (ATM inhibitor), IC86621 and NU7026 (both DNA-PK inhibitors), PF-0477736 and SB218078 (both CHK1 inhibitors).
Study reference
S Frame, RH MacKay, M Hogben, C Connolly, S Anderson, IN Fleming, S Davis, D Blake, S Green, Exploiting the unique mechanism of action of sapacitabine (CYC682) to obtain synergy with other therapeutic agents for clinical use in Acute Myeloid Leukemia, 14th Congress of the European Hematology Association (EHA), June 4-7, 2009, Berlin, Germany, Abstract 0761.
The poster is available from the Cyclacel website www.cyclacel.com and the abstract is available at http://www.eventure-online.com/eventure/publicAbstractView.do?id=102037.
About sapacitabine
Sapacitabine is an orally-available, investigational, nucleoside analog drug that acts through a dual mechanism. It interferes with DNA synthesis by causing single-strand DNA breaks and also induces arrest of cell cycle progression at G2/M-Phase. Both sapacitabine and CNDAC, its major metabolite or a substance into which the drug converts after ingestion by patients, have demonstrated potent anti-tumor activity in preclinical studies. Sapacitabine was shown to be superior in preclinical models to either gemcitabine (Gemzar®; Lilly) or ara-C, two widely used nucleoside analogs. Gemcitabine is indicated for the palliative treatment of breast, lung, pancreatic and ovarian cancer, but it has not been reported to be active in leukemias or myelodysplastic syndromes or MDS. Ara-C is indicated for the treatment of acute myeloid leukemia or AML but is typically not tolerated by elderly patients. Phase 2 trials of sapacitabine in patients with AML, MDS and non-small cell lung cancer are in progress. Sapacitabine is part of Cyclacel's deep pipeline of small molecule drugs designed to target and stop uncontrolled cell division.
About Cyclacel Pharmaceuticals, Inc.
Cyclacel is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine (CYC682), a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and lung cancer and in Phase 1 in combination with seliciclib. Seliciclib (CYC202 or R-roscovitine), a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer. CYC116, an Aurora kinase and VEGFR2 inhibitor, is in Phase 1 in patients with solid tumors. Cyclacel's ALIGN Pharmaceuticals subsidiary markets directly in the U.S. Xclair® Cream for radiation dermatitis, Numoisyn® Liquid and Numoisyn® Lozenges for xerostomia. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates. Please visit www.cyclacel.com for additional information.
Press Release Source: Cyclacel Pharmaceuticals, Inc.
Sapacitabine Has Anti-Cancer Activity in Combination With Targeted Agents and Other Nucleoside Analogs
Preclinical Data Reported At European Hematology Association Congress
On Monday June 8, 2009, 10:19 am EDT
Buzz up! Print
Related: Cyclacel Pharmaceuticals, Inc.
BERKELEY HEIGHTS, N.J., June 8, 2009 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC - News; Nasdaq:CYCCP - News) announced that Cyclacel scientists reported preclinical data supporting potential combinations of sapacitabine, a novel nucleoside analog, with novel targeted agents and other nucleoside analogs for the treatment of cancer. The combinations exploit sapacitabine's unique mechanism of action and were shown to be effective in models of leukemia and solid tumors. The data were presented at a poster presentation on Saturday, June 6 at the 14th Congress of the European Hematology Association (EHA) in Berlin, Germany.
Related Quotes
Symbol Price Change
CYCC 1.09 +0.18
"We are encouraged by the wide spectrum of anti-cancer agents that result in synergy when combined with sapacitabine. The EHA data extend previously reported data and support clinical evaluation of sapacitabine given with various anti-cancer agents as combination treatment for leukemia and other cancers," said Spiro Rombotis, President and CEO. "A week ago at the ASCO conference we reported interim Phase 2 data that pave the way for a pivotal trial of sapacitabine as a single agent in elderly patients with leukemia. We look forward to developing the broad therapeutic potential of sapacitabine to benefit patients in need of new treatment options."
The results, arising from a combination screen of over 30 compounds from several chemical families, showed robust synergy when sapacitabine was combined with inhibitors of cell cycle checkpoints, cell survival, and DNA repair, including targeted inhibitors of ATM, BCL2, CHK1, DNA-PK and PARP.
In addition, increased apoptosis or cancer cell death was observed when sapacitabine was administered in combination with other nucleoside analogs which inhibit ribonucleotide reductase, such as clofarabine and gemcitabine.
The findings extend previously reported data supporting the combination of sapacitabine with demethylating agents or HDAC inhibitors.
Specific targeted molecules presented in the abstract, inducing synergy when given in combination with sapacitabine, included: ABT-888 (PARP inhibitor), ABT-737 (BCL-2 inhibitor), KU55933 (ATM inhibitor), IC86621 and NU7026 (both DNA-PK inhibitors), PF-0477736 and SB218078 (both CHK1 inhibitors).
Study reference
S Frame, RH MacKay, M Hogben, C Connolly, S Anderson, IN Fleming, S Davis, D Blake, S Green, Exploiting the unique mechanism of action of sapacitabine (CYC682) to obtain synergy with other therapeutic agents for clinical use in Acute Myeloid Leukemia, 14th Congress of the European Hematology Association (EHA), June 4-7, 2009, Berlin, Germany, Abstract 0761.
The poster is available from the Cyclacel website www.cyclacel.com and the abstract is available at http://www.eventure-online.com/eventure/publicAbstractView.do?id=102037.
About sapacitabine
Sapacitabine is an orally-available, investigational, nucleoside analog drug that acts through a dual mechanism. It interferes with DNA synthesis by causing single-strand DNA breaks and also induces arrest of cell cycle progression at G2/M-Phase. Both sapacitabine and CNDAC, its major metabolite or a substance into which the drug converts after ingestion by patients, have demonstrated potent anti-tumor activity in preclinical studies. Sapacitabine was shown to be superior in preclinical models to either gemcitabine (Gemzar®; Lilly) or ara-C, two widely used nucleoside analogs. Gemcitabine is indicated for the palliative treatment of breast, lung, pancreatic and ovarian cancer, but it has not been reported to be active in leukemias or myelodysplastic syndromes or MDS. Ara-C is indicated for the treatment of acute myeloid leukemia or AML but is typically not tolerated by elderly patients. Phase 2 trials of sapacitabine in patients with AML, MDS and non-small cell lung cancer are in progress. Sapacitabine is part of Cyclacel's deep pipeline of small molecule drugs designed to target and stop uncontrolled cell division.
About Cyclacel Pharmaceuticals, Inc.
Cyclacel is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine (CYC682), a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and lung cancer and in Phase 1 in combination with seliciclib. Seliciclib (CYC202 or R-roscovitine), a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer. CYC116, an Aurora kinase and VEGFR2 inhibitor, is in Phase 1 in patients with solid tumors. Cyclacel's ALIGN Pharmaceuticals subsidiary markets directly in the U.S. Xclair® Cream for radiation dermatitis, Numoisyn® Liquid and Numoisyn® Lozenges for xerostomia. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates. Please visit www.cyclacel.com for additional information.
CYCC 1.27 0.27
Today 5d 1m 3m 1y 5y 10y
CYCCP 1.15 0.15
Today 5d 1m 3m 1y 5y 10y
Cyclacel & Dartmouth Researchers Report Novel Mechanism of Action for Seliciclib At AACR
Certain Lung Cancer Cells Overexpress Cyclin E and are Targeted by Seliciclib
DENVER, April 21, 2009 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) announced that scientists from Dartmouth Medical School and Cyclacel reported today preclinical evidence that certain lung cancer cells overexpress Cyclin E and are targeted by seliciclib, Cyclacel's CDK (cyclin dependent kinase) inhibitor which is currently in Phase 2 development for lung cancer. The data was presented at "Biological Mechanisms and Molecular Markers of Prevention," a symposium at the American Association of Cancer Research (AACR) Annual Meeting taking place here.
The report also suggests a novel mechanism of action for seliciclib resulting from its targeting of the CDK2/cyclin E complex: induction of anaphase catastrophe, a defect during cell division that results in apoptosis or death of cancer cells. Pending successful clinical and regulatory outcomes, lung cancers found to overexpress cyclin E may prove particularly vulnerable to molecularly targeted treatment with CDK inhibitors such as seliciclib.
Separately, Cyclacel scientists reported the discovery of novel derivatives of seliciclib with improved potency and pharmacologic properties. The novel CDK inhibitors, currently in IND-directed development, were presented at "Mechanisms of Drugs Targeting Cell Cycle Controls," a symposium at the AACR Annual Meeting.
Cyclacel scientists also reported synergistic anticancer effects on Acute Myeloid Leukemia cell lines of combinations of Cyclacel's sapacitabine with three approved drugs inhibiting either HDAC or methyltransferase enzymes. The data were presented at "Agents Targeting Histone Deacetylases and DNA Methyltransferase" a poster session at the AACR Annual Meeting.
Details of the presentations referring to specific Cyclacel programs are as follows:
Sapacitabine
Simon R. Green, Ruth H. MacKay, David E. MacCallum, Jean Melville, Sheelagh Frame, Ian N. Fleming. Cyclacel, Ltd., Dundee, United Kingdom. "Synergistic interactions between sapacitabine (CYC682) and inhibitors of either histone deacetylase or methyltransferase in Acute Myeloid Leukemia cell lines", In: Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr. 4552.
The combination of sapacitabine's primary metabolite CNDAC and the HDAC inhibitor vorinostat was evaluated in acute myeloid leukemia (AML) cells in vitro as was the combination of CNDAC with the DNA methyltransferase inhibitors azacitidine or decitabine. All combinations resulted in a synergistic induction in apoptosis leading to increased cellular cytotoxicity in the combinations compared to single agent treatments. The vorinostat-sapacitabine combination was explored in vivo in a MV4-11 AML model and demonstrated significantly improved efficacy, including tumor regression, at doses that had limited single agent activity. At the doses evaluated there was no increased toxicity in the combination groups compared to single agent treatment. An increase in apoptotic markers from tumor samples taken during the first week of dosing was observed in the combination groups compared to single agent treatment.
Seliciclib
Fabrizio Galimberti, Sarah Thompson, Xi Liu, Simon R. Green, Vincent Memoli, Duane Compton, Ethan Dmitrovsky. Dartmouth Medical School, Hanover, NH, Cyclacel Ltd., Dundee, United Kingdom. "Targeting the cyclin E-Cdk2 complex represses lung cancer growth by triggering apoptosis and anaphase catastrophe", In: Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr. 4784.
Overexpression of cyclin E leads to tumor growth in vivo. This study explored the consequences of targeting the CDK2/cyclin E complex in lung cancer cell lines. Targeting CDK2/cyclin E either genetically with small interference RNA or pharmacologically with seliciclib resulted in the inhibition of cellular proliferation of cells that appear to be "addicted" to high levels of CDK2/cyclin E. Inhibition of CDK2/cyclin E-driven tumors was observed in vivo after seliciclib treatment which also reduced the levels of proliferation markers in established tumors and the number of lung lesions in animals following intravenous injection of lung cancer cells overexpressing cyclin E two weeks prior to the start of seliciclib treatment. Molecular analysis in cell lines overexpressing cyclin E indicated that seliciclib treatment increased mitotic defects leading to anaphase catastrophe and apoptosis. These effects were enhanced by combination treatment of seliciclib with the taxanes paclitaxel or docetaxel suggesting that such combinations could be molecularly targeted in the clinic in patients with lung cancers found to overexpress cyclin E.
Simon R. Green, Sheelagh Frame, Sian Anderson, Morag Hogben, David E. MacCallum, Gavin Wood, Stuart Wilson, Paul Workman, Edward McDonald, Daniella Zheleva. Cyclacel, Ltd., Dundee, United Kingdom, The Institute of Cancer Research, London, United Kingdom. "Derivatives of seliciclib with improved potency both in vitro and in vivo as novel cyclin dependent kinase (CDK) inhibitors", In: Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr. 3863.
A library of compounds was synthesized to identify derivatives of seliciclib with increased potency and improved pharmaceutical properties. These molecules have a similar target inhibitory profile to seliciclib (CDK2/cyclin E, CDK2/cyclin A and CDK9) but have enhanced activity against their target kinases. This improved potency is reflected in their cellular cytotoxicity properties where the compounds demonstrated increased activity up to 40-fold compared to seliciclib. Detailed cellular analysis demonstrated that the molecules maintain a very similar mechanism of action to seliciclib. Metabolism studies indicated that both primary and secondary metabolism of the follow-on compounds has been improved over that of seliciclib. In xenograft models with a once a day oral dosing regimen these compounds exhibited significant anticancer activity achieving up to 90% tumor growth inhibition.
The abstracts are available online at www.aacr.org.
About Cyclacel Pharmaceuticals, Inc.
Out of money ?? What is the current value of gold??
he United States Bullion Depository Fort Knox, Kentucky
Amount of present gold holdings: 147.3 million ounces.
The only gold removed has been very small quantities used to test the purity of gold during regularly scheduled audits. Except for these samples, no gold has been transferred to or from the Depository for many years.
The gold is held as an asset of the United States at book value of $42.22 per ounce.
The Depository opened in 1937; the first gold was moved to the depository in January that year.
Highest gold holdings this century: 649.6 million ounces (December 31, 1941).
Size of a standard gold bar: 7 inches x 3 and 5/8 inches x 1 and 3/4 inches.
Weight of a standard gold bar: approximately 400 ounces or 27.5 pounds.
Construction of the depository:
Building materials used included 16,000 cubic feet of granite, 4,200 cubic yards of concrete, 750 tons of reinforcing steel, and 670 tons of structural steel.
The cost of construction was $560,000 and the building was completed in December 1936.
In the past, the Depository has stored the Declaration of Independence, the U.S. Constitution, the Articles of Confederation, Lincoln's Gettysburg address, three volumes of the Gutenberg Bible, and Lincoln's second inaugural address.
In addition to gold bullion, the Mint has stored valuable items for other government agencies. The Magna Carta was once stored there. The crown, sword, scepter, orb, and cape of St. Stephen, King of Hungary also were stored at the Depository, before being returned to the government of Hungary in 1978.
The Depository is a classified facility. No visitors are permitted, and no exc
"Party Bash Memorial Day Contest Picks"
CIT
CAR
Paige,list 2 good breakfast buffets for your $ in vegas.
tia
"Party Bash Memorial Day Contest Picks"
CAR
VILF
Florida House approves home insurance deregulation bill
> Posted by Julie Patel on April 22, 2009 10:42 AM
A measure that would roll back rate regulation for home and condo insurance was approved today by the Florida House of Representatives by a landslide vote of 105 to 13.
Rep. Bill Proctor, St. Augustine, said his bill aims to lure private insurers to the state and allow people to choose if they want to pay more for a minimally regulated policy from an insurer they trust.
State regulators would still be able to reject rates offered under the bill if they're illegally calculated or if they're not high enough.
"Let's treat our constituents like adults and allow them to choose the carrier they prefer," said Rep. Peter Nehr, R-Tarpon Springs. Insurers offering the policy must have at least $500 million in reserves or $200 million in reserves and a ratio of net premiums to surplus of 2 to 1 or lower.
Opponents -- including House Democratic Leader Franklin Sands -- say insurers could take advantage of the bill by charging as much as they want.
"There's nothing in this bill that prevents a company from charging rates that are much higher than actuarially sound rates," said Sands, D-Weston. "Each company has a mission of maximizing their profit. My concern is this could possibly lead to price gouging."
The full House and Senate would have to approve the bill in order for Gov. Charlie Crist to consider signing it into law. The Senate version of the bill is stuck in a committee that would have to approve or withdraw the bill for the idea to move forward. Crist has said recently that he supports free market approaches, but still thinks the state needs to regulate insurers.
The House and Senate will debate their versions of broad property insurance measure tomorrow that, among other things, would increase Citizens Property Insurance Corp. policyholder premiums by up to 10 percent annually and extend and shrink a $12 billion portion of the Florida Hurricane Catastrophe Fund.
Florida House approves home insurance deregulation bill
> Posted by Julie Patel on April 22, 2009 10:42 AM
A measure that would roll back rate regulation for home and condo insurance was approved today by the Florida House of Representatives by a landslide vote of 105 to 13.
Rep. Bill Proctor, St. Augustine, said his bill aims to lure private insurers to the state and allow people to choose if they want to pay more for a minimally regulated policy from an insurer they trust.
State regulators would still be able to reject rates offered under the bill if they're illegally calculated or if they're not high enough.
"Let's treat our constituents like adults and allow them to choose the carrier they prefer," said Rep. Peter Nehr, R-Tarpon Springs. Insurers offering the policy must have at least $500 million in reserves or $200 million in reserves and a ratio of net premiums to surplus of 2 to 1 or lower.
Opponents -- including House Democratic Leader Franklin Sands -- say insurers could take advantage of the bill by charging as much as they want.
"There's nothing in this bill that prevents a company from charging rates that are much higher than actuarially sound rates," said Sands, D-Weston. "Each company has a mission of maximizing their profit. My concern is this could possibly lead to price gouging."
The full House and Senate would have to approve the bill in order for Gov. Charlie Crist to consider signing it into law. The Senate version of the bill is stuck in a committee that would have to approve or withdraw the bill for the idea to move forward. Crist has said recently that he supports free market approaches, but still thinks the state needs to regulate insurers.
The House and Senate will debate their versions of broad property insurance measure tomorrow that, among other things, would increase Citizens Property Insurance Corp. policyholder premiums by up to 10 percent annually and extend and shrink a $12 billion portion of the Florida Hurricane Catastrophe Fund.